Press Releases

Year

May 03 2016

Intec Pharma Appoints VP of Clinical and Regulatory Affairs

JERUSALEM, May 3, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the appointment of Pnina Strauss-Levy as Vice President, Clinical and Regulatory Affairs. "Ms. Strauss-Levy has 15 years of experience in clinical

Apr 06 2016

Intec Pharma Expands Intellectual Property for AP-CDLD with Patent in South Korea

JERUSALEM, Israel, April 6, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the company has been informed that the Korean

Apr 04 2016

Intec Pharma Enrolls First Patient in Pivotal Phase III Clinical Trial of AP-CDLD for Advanced Parkinson's Disease Patients

JERUSALEM, April 4, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the enrollment in the U.S. of the first patient in its pivotal Phase III clinical trial for its lead product candidate, the Accordion Pill

Mar 17 2016

Mr. Zvika Joseph to Step Down as Chairman of the Board of Directors

JERUSALEM, ISRAEL--(Marketwired - Mar 17, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that Mr.

Mar 14 2016

Intec Pharma Reports 2015 Fourth Quarter and Full-Year Financial Results

JERUSALEM, ISRAEL--(Marketwired - Mar 14, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), an Israeli clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced its financial results for the year ended

Mar 14 2016

Intec Pharma Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website

JERUSALEM, ISRAEL--(Marketwired - Mar 14, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that its annual report on Form 20-F, containing

Mar 14 2016

Intec Pharma Ltd.: Notice of Special General Meeting of Shareholders

JERUSALEM, ISRAEL--(Marketwired - Mar 14, 2016) - Notice is hereby given that the special general meeting of shareholders of Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP) (the " Company "), will be held at the offices of Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co., One Azrieli Center, Round

Mar 10 2016

Intec Pharma Completed a Phase I Clinical Trial With Its Third Pipeline Product

JERUSALEM, ISRAEL--(Marketwired - Mar 10, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has completed a Phase I clinical trial with

Jan 05 2016

Intec Pharma to Present at Biotech Showcase 2016

JERUSALEM, ISRAEL--(Marketwired - Jan 5, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that its Chief Executive Officer, Zeev Weiss, will

Dec 16 2015

Intec Pharma Further Expands Intellectual Property With a New Patent for the Accordion Pill Zaleplon in Europe

JERUSALEM, ISRAEL--(Marketwired - Dec 16, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the Company has been informed by the European

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Next page
Last page

Displaying 81 - 90 of 96